Allogeneic WTX-212C in Advanced Solid Tumors

This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options. The study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.

NCT Number	NCT07556653
Lead Sponsor	Zhejiang Provincial People's Hospital Collaborators: Westlake Therapeutics, First People's Hospital of Hangzhou
Conditions	Advanced Solid Tumors
Enrollment	24 participants
Start Date	2026-06-26
Primary Completion	2027-04-09 (estimated)
Study Completion	2028-04-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-14